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bronchopulmonary disease. A comparison was made of the effects of administering inactivated bivalent influenza vaccine to 30 patients with chronic chest disease by various routes. The vaccine was given by subcutaneous injection to one group, by intranasal and intraoral spray on two successive days to a second group, and by both subcutaneous and intranasal routes to a third group of patients. Most of the patients suffered from chronic bronchitis with airways obstruction but three had asthma. The composition of the groups was adjusted in order that approximately the same number was present in each group of those with or without antibodies to influenza virus A2/Hong Kong/68. The titre of antibodies to this virus was measured in the serum and in sputum before and after immunization.
The results were clearcut in that a greater proportion of those receiving subcutaneous vaccine with or without intranasal vaccine achieved a rise in HI antibodies and a higher titre of serum antibodies than those receiving vaccine purely by the respiratory route. Sputum antibodies were measured by both HI and tissue culture neutralization tests. The best sputum antibody responses were achieved by those receiving a single dose of subcutaneous vaccine. Those receiving vaccine by the respiratory route only achieved the poorest result and the third group immunized by both routes produced intermediate titres of sputum antibodies, thus suggesting an impairment of the local antibody response. These results are discussed with reference to the method of immunization against influenza of patients with chronic bronchitis.
Because of their disturbed ventilatory function, patients with chronic chest disease, such as chronic bronchitis and asthma, suffer severely from the effects of influenza and other acute respiratory infections. The use of prophylactic measures either to prevent or to ameliorate such infections is therefore indicated in the management of these patients. One such measure is influenza vaccination, which, in Britain and the United States, is currently recommended for all patients with chronic bronchopulmonary disorders and other groups at special risk.
Despite the use of influenza vaccines for a number of years, however, many questions still remain. These include the degree of clinical protection and efficacy, the most suitable form of (Waldman et al., 1970) . Of the total vaccine volume of 1-5 ml, 0 75 ml was given into the oropharynx during inspiration and the remainder was then given equally into Sputum was collected seven days before vaccination, on the day of vaccination, and on days 7, 14, and 28 post-vaccination. Early morning specimens were brought to the clinic in clean sputum cups, usually within two to three hours of expectoration. A few specimens were kept at home in a refrigerator or cold pantry for six to eight hours. This posed no problem since sputum specimens kept in our laboratory at temperatures up to 37'C for similar periods of time showed no diminution in immunoglobulin concentration or antibody titre. All specimens were visibly inspected to rule out the presence of gross blood or unusual salivary contamination and were then frozen at -20'C. Only about 5-10% of specimens were grossly purulent; most were very tenacious and grey-white in colour. Processing of the thawed sputa was by a modification of the method of Waldman et al. (1970) in order to facilitate comparison of data. The specimens were thawed, and penicillin (100 units/ml) and streptomycin (100 jig/ml) were added. After dialysis for 24 hours against 20 volumes of distilled water containing antibiotics at 4°C, the sputa were homogenized 'by being shaken vigorously for 30 seconds with glass beads. A sufficient amount of phosphate-buffered saline, pH 7*4 (PBS), was added before the shaking to ensure separation of the gel and sol phases after centrifugation at 2,500 rpm for 30 minutes. About half of the sputa required only an equal volume of PBS for proper separation, whereas the remaining specimens required two or three (rarely four) volumes of PBS. In general, sputa taken from the same patient on different occasions required the same amount of PBS diluent. The final dilution required did not have any appreciable effect on final protein concentration. The supernatant (sol phase) was then tested for total protein, individual proteins, and antibody by the methods described below. Nasal washings were collected by instilling a total of 10 ml of sterile PBS into the nares in 1-5 to 2-0 ml aliquots followed by forceful expulsion into a Petri dish. The expelled material was processed as previously described (Downie and Stuart-Harris, 1970 , 1953) . Before testing, the specimens were treated with cholera filtrate (Burroughs Wellcome Limited) as described previously (Potter et al., 1972) . Eight HAU were used to test sera and 4 HAU to test sputa and nasal washes. Titrations for neutralizing antibody were carried out by the quantitative haemadsorption technique (Finter, 1967) as described previously (Potter et al., 1972) . All specimens were heated to 56°C for 30 minutes before testing and were incubated with 100 tissue culture doses of influenza virus A2/Hong Kong/68 prior to inoculation of primary monkey kidney cells.
Sera were tested for complement-fixing antibodies to influenza A group-specific antigen (Downie and Stuart-Harris, 1970) . The antigen was extracted from chick embryos infected with A2/Hong Kong/68 virus.
PROTEIN DETERMINATION Processed sputa and nasal washes were assayed for protein by the method of Lowry, Rosebrough, Farr, and Randall (1951) . QUANTITATIVE IMMUNOASSAY Goat antiser to human IgG, IgM, and IgA, and rabbit antisera to human serum albumin (HSA) and lactoferrin were prepared and their specificity confirmed both in reverse radial immunodiffusion as previously described (Reimer, Phillips, Maddison, and Shore, 1970; Phillips et al., 1971; Shore, Phillips, and Reimer, 1971 ) and in Ouchterlony analysis (OA) and immunoelectrophoresis (IEP) against pooled sputum, nasal washes, and serum. The anti-IgA, made against an 1IS secretory IgA from human milk, did not react with secretory piece at the dilution used in the IgA quantitation test.
The following antigen standards were employed for immunoquantitation: commercially prepared IgG and HSA (Schwarz/Mann, Orangeburg, NY, USA), an llS secretory IgA (Reimer et al., 1970) for quantitation of IgA in secretions, and lactoferrin from human milk (Johansson, 1969) . All antigens were evaluated for purity in OA and IEP. The extinction coefficients employed were 13-8 for both IgG (Schultze and Heremans, 1966) and secretory IgA (Tomasi and Bienenstock, 1968) and 117 for lactoferrin (Montreuil, Tonnelat, and Mullet, 1960) . For measurement of IgA in serum as well as IgM, a pooled normal human serum was used and concentrations of 2-00 mg/ml for IgA and 1-00 mg/ml for IgM were assumed.
The level of selected proteins in serum, sputum, and nasal wash was determined by radial immunodiffusion (Mancini, Carbonara, and Heremans, 1965 IFor purposes of computation, negative titres (< 2) are assigned a value of 1. 3G
Rises in sputum antibody in all three vaccine groups were accompanied by rises in serum antibody titre. From a quantitative standpoint, however, although there was a tendency for the highest sputum antibody responses to parallel the strongest serum antibody responses, the correlation between the two was not invariable. For example, a few patients with very large rises in serum antibody after vaccination showed only modest increases in sputum antibody compared to other patients with equivalent serum antibody rises and serum antibody titres. This observed variation from patient to patient could not be explained simply by a consideration of the serum/sputum IgG ratios in the different subjects. In particular, when compared at equivalent serum antibody titres, patients in group A had higher sputum antibody titres than patients in group C. This phenomenon is reflected in Tables III, IV , and V, where a higher sputum HI and neutralizing GMT at 28 days was found in group A as compared to group C despite similar serum HI antibody GMTs. Of the three patients in the aerosol group (B) who showed a four-fold or greater serum antibody rise, only one had a significant rise in sputum antibody.
The presence or absence of sputum antibody before vaccination did not have any noticeable influence on the subsequent response to vaccine. NASAL ANTIBODY RESPONSE. The results obtained for the nasal antibody response are more difficult to interpret than the sputum antibody data because of technical problems. Owing to their difficulty in breathing, the majority of patients tolerated the nasal wash procedure rather poorly and were able to expel only small or irregular amounts of wash effluate. As a result, striking variations in the content of IgA and IgG, occasionally as high as fiveto 10-fold, were found in specimens taken from the same patient at different times in the study. Even after four-to five-fold concentrations of the nasal specimens, the average concentration of the two immunoglobulins was lower than in the sputum specimens, approximately four-fold lower for IgG and nine-fold lower for IgA. In addition, the volume of the specimens obtained from some patients precluded doing the full battery of tests; on occasion, pooling of several post-vaccination specimens from the same patient was necessary to provide an adequate specimen volume for testing.
With these reservations, the nasal antibody data, uncorrected for IgA or IgG concentration, are as follows. HI Gwaltney, Edmondson, Rothenberg, and White (1971) , who found a decisively better response to parenteral than to aerosol vaccine in normal subjects. Unfortunately, measurements of sputum or nasal antibodies were not reported in their study.
Our findings are somewhat at variance with those of Waldman et al. (1970) , who found a fourfold or greater rise in the sputum neutralizing antibody titre after aerosol immunization in each of seven patients with chronic lung disease in the United States. This group of investigators also reported a failure of parenteral vaccine, in a similar dosage to ours, to stimulate a sputum neutralizing antibody response; however, in their paper it is not clear whether the subjects given parenteral vaccine were patients with severe chronic lung disease or simply 'normal' volunteers who could produce small amounts of thin scanty sputum because of smoking. To some extent the different results in the two studies may be due to the fact that the earlier study employed a different virus vaccine strain (an earlier Asian A2 strain) and immunized a group of patients with a higher serum antibody titre against the homologous virus. In our present study, over half of our patients were seronegative to the A2/Hong Kong/68 virus employed in the vaccine. It has been reported that healthy seropositive persons have a better nasal antibody response to local respiratory vaccine than do seronegative individuals; the latter tend to respond with the production of serum antibody but not nasal antibody (Rossen et al. 1971 ). Three of our seronegative patients in group B (aerosol group) showed this phenomenon of serum antibody response unaccompanied by detectable respiratory antibody formation. None of the seropositive patients behaved in this way.
The nature of the antibody found in the sputum of the parenterally immunized patients is of interest. It seems likely that at least a portion of the sputum antibody is derived from the serum in those individuals with high post-vaccination serum antibody titres. This follows from the observations that human serum antibody stimulated by inactivated influenza vaccine is of the IgG class (Waldman, Mann, and Kasel, 1967) and that most of the sputum IgG in chronic bronchitic patients is serum-derived rather than locally produced (Shore et al., in preparation) . Although the IgG concentration is approximately 200-fold lower in sputum than in serum (Table V) , high titres of serum IgG antibody (>384, for example) would be expected to produce measurable levels of antibody in sputum by simple diffusion. It is unlikely, however, that all of the sputum antibody is derived from the serum for a number of reasons. First, a comparison of the ratios of antibody to IgG concentration in sputum and serum suggests that an excessive amount of antibody is present in sputum. Secondly, there is an imperfect correlation of sputum and serum antibody titres. This is best demonstrated by a comparison of vaccine groups A and C, both of which demonstrated similar postvaccination geometric titres in serum but different antibody titres in sputum. Thus, it is probable that part of the sputum antibody in these patients was produced locally in the respiratory tract. It is not known at present whether this local antibody belongs to either the IgA or IgG class of immunoglobulins, although preliminary studies in our laboratory using density gradient ultracentrifugation imply a contribution of antibody of the secretory IgA type as well as of the IgG type.
Contrary to a previous report (Medici and Buergi, 1971) , the patients with chronic bronchitis in the present study produced adequate amounts of secretory IgA in their sputum (Shore et al., in preparation) . Locally produced or actively transported IgG was also present in their sputum in small amounts (Shore et al., in preparation) so that not all local antibody is necessarily of the IgA class.
Because of the increased risk of complications from influenzal disease in patients with chronic bronchopulmonary disease, it is important to know that immunization with a standard dose of influenza vaccine given by the standard subcutaneous route can produce good levels of sputum as well as serum antibodies. Whether sputum antibodies have a role in preventing lower respiratory involvement and complications in influenza infection remains to be demonstrated.
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